Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Bayesian spatio-temporal modelling of tobacco-related cancer mortality in Switzerland
Jürgens V, ess s, Phuleria H, Früh M, Schwenkglenks M, Frick H, Cerny T, Vounatsou P. Bayesian spatio-temporal modelling of tobacco-related cancer mortality in Switzerland. Geospat Health 2013; 7:219-36.
01.05.2013Bayesian spatio-temporal modelling of tobacco-related cancer mortality in Switzerland
01.05.2013Geospat Health 2013; 7:219-36
Jürgens Verena, ess silvia, Phuleria Harish C, Früh Martin, Schwenkglenks Matthias, Frick Harald, Cerny Thomas, Vounatsou Penelope
Dying is a Transition
Renz M. Dying is a Transition. Am J Hosp Palliat Care 2013; 30:283-290.
01.05.2013Dying is a Transition
01.05.2013Am J Hosp Palliat Care 2013; 30:283-290
Renz Monika
Radiation-induced cavernoma after total body irradiation and haematopoietic stem cell transplantation in an adult patient suffering from acute myeloid leukaemia
Walch J, Tettenborn B, Weber J, Hundsberger T. Radiation-induced cavernoma after total body irradiation and haematopoietic stem cell transplantation in an adult patient suffering from acute myeloid leukaemia. Case Rep Neurol 2013; 5:91-7.
18.04.2013Radiation-induced cavernoma after total body irradiation and haematopoietic stem cell transplantation in an adult patient suffering from acute myeloid leukaemia
18.04.2013Case Rep Neurol 2013; 5:91-7
Walch Julia, Tettenborn Barbara, Weber Johannes, Hundsberger Thomas
Radiation-induced cavernoma after total body irradiation and haematopoietic stem cell transplantation in an adult patient suffering from acute myeloid leukaemia
Hundsberger T, Weber J, Tettenborn B, Walch J. Radiation-induced cavernoma after total body irradiation and haematopoietic stem cell transplantation in an adult patient suffering from acute myeloid leukaemia. Case Reports in Neurology 2013; 5:91-97.
18.04.2013Radiation-induced cavernoma after total body irradiation and haematopoietic stem cell transplantation in an adult patient suffering from acute myeloid leukaemia
18.04.2013Case Reports in Neurology 2013; 5:91-97
Hundsberger Thomas, Weber Johannes, Tettenborn Barbara, Walch Julia
Psychosocial consequences of cancer cachexia: the development of an item bank
Häne H, Oberholzer R, Walker J, Hopkinson J, de Wolf-Linder S, Strasser F. Psychosocial consequences of cancer cachexia: the development of an item bank. J Pain Symptom Manage 2013; 46:795-806.
17.04.2013Psychosocial consequences of cancer cachexia: the development of an item bank
17.04.2013J Pain Symptom Manage 2013; 46:795-806
Häne Hanspeter, Oberholzer Rolf, Walker Jochen, Hopkinson Jane B, de Wolf-Linder Susanne, Strasser Florian
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)
Templeton A, Schiess R, Wild P, Rüschoff J, Thalmann G, Dietrich P, Aebersold R, Klingbiel D, Gillessen Sommer S, Müller B, Winterhalder R, Stenner F, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C, Gautschi O, Borner M, Fechter E, Swiss Group for Clinical Cancer Research (SAKK). Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol 2013; 64:150-8.
06.04.2013Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)
06.04.2013Eur Urol 2013; 64:150-8
Templeton Arnoud, Schiess Ralph, Wild Peter J, Rüschoff Jan H, Thalmann George, Dietrich Pierre-Yves, Aebersold Ruedi, Klingbiel Dirk, Gillessen Sommer Silke, Müller Beat, Winterhalder Ralph, Stenner Frank, Dutoit Valérie, Cathomas Richard, Rothermundt Christian, Bärtschi Daniela, Dröge Cornelia, Gautschi Oliver, Borner Markus, Fechter Eva, Swiss Group for Clinical Cancer Research (SAKK)
Lung histology predicts outcome of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
Holbro A, Lehmann T, Girsberger S, Stern M, Gambazzi F, Lardinois D, Heim D, Passweg J, Tichelli A, Bubendorf L, Savic S, Hostettler K, Grendelmeier P, Halter J, Tamm M. Lung histology predicts outcome of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013; 19:973-80.
02.04.2013Lung histology predicts outcome of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
02.04.2013Biol Blood Marrow Transplant 2013; 19:973-80
Holbro Andreas, Lehmann Thomas, Girsberger Sabine, Stern Martin, Gambazzi Franco, Lardinois Didier, Heim Dominik, Passweg Jakob R, Tichelli André, Bubendorf Lukas, Savic Spasenija, Hostettler Katrin, Grendelmeier Peter, Halter Joerg P, Tamm Michael
Factors influencing the success of in vivo sentinel lymph node procedure in colon cancer patients: Swiss prospective, multicenter study sentinel lymph node procedure in colon cancer
Viehl C, Gueller U, Langer I, Laffer U, Oertli D, Zuber M. Factors influencing the success of in vivo sentinel lymph node procedure in colon cancer patients: Swiss prospective, multicenter study sentinel lymph node procedure in colon cancer. World J Surg 2013; 37:873-7.
01.04.2013Factors influencing the success of in vivo sentinel lymph node procedure in colon cancer patients: Swiss prospective, multicenter study sentinel lymph node procedure in colon cancer
01.04.2013World J Surg 2013; 37:873-7
Viehl Carsten T, Gueller Ulrich, Langer Igor, Laffer Urban, Oertli Daniel, Zuber Markus
[Cancer screening - principles, evaluation and implementation]
Egger M, Zwahlen M, Cerny T. [Cancer screening - principles, evaluation and implementation]. Ther Umsch 2013; 70:195-203.
01.04.2013[Cancer screening - principles, evaluation and implementation]
01.04.2013Ther Umsch 2013; 70:195-203
Egger Matthias, Zwahlen Marcel, Cerny Thomas
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44)
Huober J, Kümmel S, Mau C, Jackisch C, Khandan F, Costa S, Krabisch P, Loibl S, Nekljudova V, Untch M, Höß C, Gerber B, Fasching P, Hanusch C, Rezai M, Eidtmann H, Kittel K, Hilfrich J, Schwedler K, Blohmer J, Tesch H, Minckwitz G. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44). Eur J Cancer 2013; 49:2284-93.
27.03.2013Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44)
27.03.2013Eur J Cancer 2013; 49:2284-93
Huober Jens, Kümmel Sherko, Mau Christine, Jackisch Christian, Khandan Fariba, Costa Serban Dan, Krabisch Petra, Loibl Sibylle, Nekljudova Valentina, Untch Michael, Höß Cornelia, Gerber Bernd, Fasching Peter A, Hanusch Claus, Rezai Mahdi, Eidtmann Holger, Kittel Kornelia, Hilfrich Jörn, Schwedler Kathrin, Blohmer Jens-Uwe, Tesch Hans, Minckwitz Gunter von
Multidisciplinary care in patients with prostate cancer: room for improvement
Strebel R, Winterhalder R, Morant R, Pless M, Huber U, Fehr M, Gillessen Sommer S, Schmid H, Sulser T, Cathomas R. Multidisciplinary care in patients with prostate cancer: room for improvement. Support Care Cancer 2013; 21:2327-33.
26.03.2013Multidisciplinary care in patients with prostate cancer: room for improvement
26.03.2013Support Care Cancer 2013; 21:2327-33
Strebel Räto T, Winterhalder Ralph, Morant Rudolf, Pless Miklos, Huber Urs, Fehr Martin, Gillessen Sommer Silke, Schmid Hans-Peter, Sulser Tullio, Cathomas Richard
Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors
Templeton A, Thürlimann B, Baumann M, Mark M, Stoll S, Schwizer M, Dietrich D, Ruhstaller T. Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors. BMC cancer 2013; 13:153.
25.03.2013Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors
25.03.2013BMC cancer 2013; 13:153
Templeton Arnoud J, Thürlimann Beat, Baumann Michael, Mark Michael, Stoll Sarah, Schwizer Madeleine, Dietrich Daniel, Ruhstaller Thomas
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer
Sandhu S, Assiotis I, Olmos D, Yap T, Fong P, Tunariu N, Koh D, Molife L, Kaye S, Lord C, Ashworth A, Fenwick K, Campbell J, Omlin A, Hylands L, Miranda S, Barber L, Riisnaes R, Reid A, Attard G, Chen L, Kozarewa I, Gevensleben H, de Bono J. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Ann Oncol 2013; 24:1416-8.
22.03.2013Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer
22.03.2013Ann Oncol 2013; 24:1416-8
Sandhu S K, Assiotis I, Olmos D, Yap T A, Fong P, Tunariu N, Koh D, Molife L R, Kaye S, Lord C J, Ashworth A, Fenwick K, Campbell J, Omlin Aurelius, Hylands L, Miranda S, Barber L J, Riisnaes R, Reid A H, Attard G, Chen L, Kozarewa I, Gevensleben H, de Bono J
Development of therapeutic combinations targeting major cancer signaling pathways
Yap T, Omlin A, de Bono J. Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol 2013; 31:1592-605.
18.03.2013Development of therapeutic combinations targeting major cancer signaling pathways
18.03.2013J Clin Oncol 2013; 31:1592-605
Yap Timothy A, Omlin Aurelius, de Bono Johann S
Das Ich stirbt in ein Du hinein
Renz M (2013). Das Ich stirbt in ein Du hinein - Sterben als spirituelle Erfahrung. Präsentiert bei: Welttag der Kranken, Katholische Universität Eichstätt
08.03.2013Das Ich stirbt in ein Du hinein
08.03.2013Welttag der Kranken
Renz Monika
Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
Kampa-Schittenhelm K, Heinrich M, Akmut F, Döhner H, Döhner K, Schittenhelm M. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Mol Cancer 2013; 12:19.
07.03.2013Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
07.03.2013Mol Cancer 2013; 12:19
Kampa-Schittenhelm Kerstin, Heinrich Michael Charles, Akmut Figen, Döhner Hartmut, Döhner Konstanze, Schittenhelm Marcus
Perioperative Blood Transfusions Do Not Impact Overall and Disease-Free Survival After Curative Rectal Cancer Resection: A Propensity Score Analysis
Warschkow R, Gueller U, Köberle D, Mueller S, Steffen T, Thurnheer M, Schmied B, Tarantino I. Perioperative Blood Transfusions Do Not Impact Overall and Disease-Free Survival After Curative Rectal Cancer Resection: A Propensity Score Analysis. Ann Surg 2013; 259:131-138.
06.03.2013Perioperative Blood Transfusions Do Not Impact Overall and Disease-Free Survival After Curative Rectal Cancer Resection: A Propensity Score Analysis
06.03.2013Ann Surg 2013; 259:131-138
Warschkow Rene, Gueller Ulrich, Köberle Dieter, Mueller Sascha, Steffen Thomas, Thurnheer Martin, Schmied Bruno, Tarantino Ignazio
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
Drukker C, van de Vijver M, Rutgers E, Sonke G, van 't Veer L, Knauer M, Roumen R, Wesseling J, van Tinteren H, van Harten W, Retèl V, Bueno-de-Mesquita J, Linn S. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer 2013; 133:929-36.
04.03.2013A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
04.03.2013Int J Cancer 2013; 133:929-36
Drukker C A, van de Vijver M J, Rutgers E J T, Sonke G S, van 't Veer L J, Knauer Michael, Roumen R M H, Wesseling J, van Tinteren H, van Harten W H, Retèl V P, Bueno-de-Mesquita J M, Linn S C
Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
Kraus M, Bader J, Overkleeft H, Driessen C. Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance. Blood Cancer J 2013; 3:e103.
01.03.2013Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
01.03.2013Blood Cancer J 2013; 3:e103
Kraus Marianne, Bader J, Overkleeft H, Driessen Christoph
Concomitant cholecystectomy during laparoscopic Roux-en-Y gastric bypass in obese patients is not justified: a meta-analysis
Warschkow R, Tarantino I, Ukegjini K, Beutner U, Gueller U, Schmied B, Mueller S, Schultes B, Thurnheer M. Concomitant cholecystectomy during laparoscopic Roux-en-Y gastric bypass in obese patients is not justified: a meta-analysis. Obes Surg 2013; 23:397-407.
01.03.2013Concomitant cholecystectomy during laparoscopic Roux-en-Y gastric bypass in obese patients is not justified: a meta-analysis
01.03.2013Obes Surg 2013; 23:397-407
Warschkow Rene, Tarantino Ignazio, Ukegjini Kristjan, Beutner Ulrich, Gueller Ulrich, Schmied Bruno, Mueller Sascha, Schultes Bernd, Thurnheer Martin